Neurogene Inc. Current Assets
Neurogene Inc. (NGNE) had Current Assets of $228.91 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-11
- 2026-06-30: Assets, Current $228.91M.
- 2026-03-31: Assets, Current $246.75M.
- 2025-12-31: Assets, Current $271.77M.
- 2025-09-30: Assets, Current $270.52M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $228.91M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $246.75M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $271.77M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $270.52M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $278.99M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $296.40M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $315.92M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $143.65M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $159.15M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $174.14M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $200.35M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $79.89M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $83.78M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $85.64M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $84.72M 10-K · filed 2024-03-18 | $99.13M 10-K · filed 2023-03-20 |
| 2022-09-30 | $108.86M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $118.48M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $130.37M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $143.99M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $156.50M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $167.50M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $181.31M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $194.52M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $206.59M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $131.00M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $139.65M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $143.60M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $67.58M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $73.21M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $74.83M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $77.17M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $87.29M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $103.24M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $94.22M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $108.83M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $120.57M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $132.19M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $122.44M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $103.48M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $146.61M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $67.65M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $69.49M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $74.80M 10-K · filed 2017-03-09 | |
| 2015-09-30 | $117.94M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $29.76M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $35.02M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $39.30M 10-K · filed 2016-03-14 | $39.30M 10-K · filed 2015-03-16 |
| 2014-09-30 | $40.36M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $36.34M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $56.25M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $15.30M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |